Literature DB >> 7351950

The importance of circulating 1,25-dihydroxyvitamin D in the pathogenesis of hypercalciuria and renal-stone formation in primary hyperparathyroidism.

A E Broadus, R L Horst, R Lang, E T Littledike, H Rasmussen.   

Abstract

Fifty patients with primary hyperparathyroidism were studied with an oral calcium-tolerance test, measurements of plasma levels of vitamin D metabolites, and determination of calcium excretion on both a low-normal (400 mg) and high-normal (1000 mg) calcium intake. There were strong positive correlations between plasma levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) and both the calciuric response to the calcium-tolerance test (r = +0.75, P less than 0.001) and calcium excretion on the 1000-mg calcium diet (r = +0.65, P less than 0.001). The patients were classified into two subpopulations: 30 patients showed hyperabsorption with the calcium-tolerance test, striking hypercalciuria, marked elevations in plasma 1,25(OH)2D, and a high incidence (19 of 30 patients) of renal stones; 20 patients had a normal response to the tolerance test, normocalciuria, normal or high-normal plasma 1,25(OH)2D, and a low incidence of stones (three of 20 patients). The findings emphasize the importance of circulating 1,25(OH)2D in the pathogenesis of hypercalciuria and stone formation in primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7351950     DOI: 10.1056/NEJM198002213020801

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  32 in total

1.  Occult urolithiasis in asymptomatic primary hyperparathyroidism.

Authors:  Yu-Kwang Donovan Tay; Minghao Liu; Leonardo Bandeira; Mariana Bucovsky; James A Lee; Shonni J Silverberg; Marcella D Walker
Journal:  Endocr Res       Date:  2018-02-05       Impact factor: 1.720

2.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

3.  Hypercalcemic States associated with nephrolithiasis.

Authors:  Brandon L Craven; Corey Passman; Dean G Assimos
Journal:  Rev Urol       Date:  2008

4.  Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats.

Authors:  T Shinki; Y Ueno; H F DeLuca; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Vitamin D deficiency and hyperparathyroidism with severe bone disease.

Authors:  S G Ingemansson; C H Hugosson; N J Woodhouse
Journal:  World J Surg       Date:  1988-08       Impact factor: 3.352

Review 6.  Bone mineral content in calcium renal stone formers.

Authors:  A Trinchieri
Journal:  Urol Res       Date:  2005-08-03

7.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

8.  The cause of maintained hypercalciuria after the surgical cure of primary hyperparathyroidism is a defect in renal calcium reabsorption.

Authors:  M L Farias; A G Delgado; D Rosenthal; J G Vieira; T Kasamatsu; M J Lazarevitch; M F Pereira; M B Lima
Journal:  J Endocrinol Invest       Date:  1996-01       Impact factor: 4.256

9.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

Review 10.  Asymptomatic primary hyperparathyroidism.

Authors:  Shonni J Silverberg; Marcella D Walker; John P Bilezikian
Journal:  J Clin Densitom       Date:  2013 Jan-Mar       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.